** Shares of PTC Therapeutics PTCT.O rise 4.6% to $55.17 in morning trade
** Brokerage J.P.Morgan raises PT to $78 from $72, representing a 47.8% upside to the stock's last close
** "We continue to see PTCT shares as under-appreciated by the Street ahead of two compelling launches in established markets" - J.P. Morgan says
** PTC expects regulatory decisions on co's drugs - sepiapterin to treat the genetic condition phenylketonuria (PKU), and vatiquinone to treat nervous system disorder Friedreich ataxia - this year
** Brokerage says current peak sales estimate of ~$700 mln by 2031 for sepiapterin is "overly conservative"
** Nine of 15 brokerages rate the stock "buy" or higher, four "hold", two "sell" or lower; their median PT is $63.92, according to data compiled by LSEG
** Up to last close, PTCT has risen 71.3% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。